皮下与静脉注射Trastuzumab:最小化成本分析与来自秘鲁癌症参考中心的真实世界数据
Iris Otoya1,2, Natalia Valdiviezo1,3, Katia Roque1,4,5
1Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima 15038, Perú.
Ecancermedicalscience
|July 18, 2024
概括
皮下施用trastuzumab显著降低了秘鲁的乳腺癌治疗成本,每名患者大约节省了S/15,049.09. 这种方法为在资源有限的环境中管理HER2阳性乳腺癌提供了更具成本效益的方法.
科学领域:
- 在瘤学瘤学.
- 药物经济学 药物经济学
背景情况:
- 乳腺癌 (BC) 是全球健康面临的重大挑战,秘鲁的发病率和死亡率很高.
- 特拉斯图祖马布是人类表皮生长因子受体2-阳性 (HER2+) BC的重要疗法,可用于静脉注射 (IV) 和皮下注射 (SC) 配方.
研究的目的:
- 为了比较IV和SC施用trastuzumab的成本.
- 评估SC trastuzumab在秘鲁国家新生病研究所 (INEN) 的经济影响.
主要方法:
- 使用INEN (秘鲁) 的真实数据进行回顾性成本分析.
- 与IV和SC施用trastuzumab相关的直接医疗成本的比较.
主要成果:
- 与静脉注射相比,SC型特拉斯图祖马布的使用使得每名患者的平均成本降低了S/15,049.09.
- 全球数据表明,由于SC的效率和成本效益,SC管理的偏好越来越大.
结论:
- 在秘鲁,SC trastuzumab 是 HER2+ 乳腺癌的更具成本效益的治疗选择.
- 研究结果支持在资源有限的医疗保健系统中优化瘤治疗的知情决策,同时考虑当地环境.
关键词:
在HER2阳性的情况下,HER2是阳性的.秘鲁 秘鲁 秘鲁 秘鲁 是一个这就是Trastuzumab.乳腺癌 乳腺癌 乳腺癌费用 费用 费用 费用 费用 费用静脉内注射的 静脉内注射皮下注射 皮下注射 皮下注射更多相关视频
10:38Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Published on: December 16, 2022
2.1K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.6K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...